CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Processa Pharmaceuticals, Inc. (PCSA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Processa Pharmaceuticals, Inc. (PCSA)

Pharmaceutical Preparations · market cap $5M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-19 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
  • 2026-11-19 (est.)Earningsimp 5/10
Pipeline
AssetPhaseIndication
PCS12852Phase 2Gastroparesis
PCS6422 and capecitabinePhase 2Breast Cancer
RX-3117Phase 2Metastatic Pancreatic Cancer
PCS499Phase 2Necrobiosis Lipoidica
Price & technical context
3-month
-16.7%
6-month
-36.4%
12-month
-76.0%
52-wk range
$1.35–$7.65
vs 50-day MA
-3.0%
vs 200-day MA
-23.5%
Realized vol
159.4%
Max drawdown
-96.2%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for PCSA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.